Markus A. Kuczyk

TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.

TL;DR: The cumulative dose of P was a major predictor for toxicity and patients and treatment characteristics such as noise exposure, age, history of smoking, and mode of B application were less important.

TL;DR: HDCT, including etoposide doses greater than 2 g/m2, is associated with an acceptably low incidence of s-AML in patients with advanced GCT, as compared with the age-matched general population.

TL;DR: Considering the particularly unfavorable prognostic characteristics of this patient population compared with patients from previous trials for new drugs in germ cell cancer, eg, paclitaxel and gemcitabine, a 13% overall response rate and a 19% response rate in the group treated with oxaliplatin 130 mg/m(2) seems to be of interest.

TL;DR: Complete resection of metachronous liver metastases can be achieved in the majority of patients, however, significant morbidity and mortality as well as the limited prognosis even after R0 resection strongly suggest careful patient selection.